A role for the circadian transcription factor NPAS2 in the progressive loss of non-rapid eye movement sleep and increased arousal during fentanyl withdrawal in male mice
- 1 August 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Psychopharmacology
- Vol. 239 (10), 3185-3200
- https://doi.org/10.1007/s00213-022-06200-x
Abstract
Rationale Synthetic opioids like fentanyl are contributing to the rise in rates of opioid use disorder and drug overdose deaths. Sleep dysfunction and circadian rhythm disruption may worsen during opioid withdrawal and persist during abstinence. Severe and persistent sleep and circadian alterations are putative factors in opioid craving and relapse. However, very little is known about the impact of fentanyl on sleep architecture and sleep–wake cycles, particularly opioid withdrawal. Further, circadian rhythms regulate sleep–wake cycles, and the circadian transcription factor, neuronal PAS domain 2 (NPAS2) is involved in the modulation of sleep architecture and drug reward. Here, we investigate the role of NPAS2 in fentanyl-induced sleep alterations. Objectives To determine the effect of fentanyl administration and withdrawal on sleep architecture, and the role of NPAS2 as a factor in fentanyl-induced sleep changes. Methods Electroencephalography (EEG) and electromyography (EMG) was used to measure non-rapid eye movement sleep (NREMS) and rapid eye movement sleep (REMS) at baseline and following acute and chronic fentanyl administration in wild-type and NPAS2-deficient male mice. Results Acute and chronic administration of fentanyl led to increased wake and arousal in both wild-type and NPAS2-deficient mice, an effect that was more pronounced in NPAS2-deficient mice. Chronic fentanyl administration led to decreased NREMS, which persisted during withdrawal, progressively decreasing from day 1 to 4 of withdrawal. The impact of fentanyl on NREMS and arousal was more pronounced in NPAS2-deficient mice. Conclusions Chronic fentanyl disrupts NREMS, leading to a progressive loss of NREMS during subsequent days of withdrawal. Loss of NPAS2 exacerbates the impact of fentanyl on sleep and wake, revealing a potential role for the circadian transcription factor in opioid-induced sleep changes.This publication has 52 references indexed in Scilit:
- Circadian clock genes and sleep homeostasisEuropean Journal of Neuroscience, 2009
- NPAS2 as a transcriptional regulator of non-rapid eye movement sleep: Genotype and sex interactionsProceedings of the National Academy of Sciences of the United States of America, 2006
- Sleep disturbances among methadone maintained patientsJournal of Substance Abuse Treatment, 2004
- Altered Patterns of Sleep and Behavioral Adaptability in NPAS2-Deficient MiceScience, 2003
- The Effectiveness of Combined Naloxone/Lofexidine in Opiate Detoxification: Results from a Double‐blind Randomized and Placebo‐controlled TrialThe American Journal on Addictions, 2003
- The Effectiveness of Combined Naloxone/Lofexidine in Opiate Detoxification: Results from a Double-blind Randomized and Placebo-controlled TrialThe American Journal on Addictions, 2003
- Coping behaviors and relapse precipitants in opioid dependence: A study from North IndiaJournal of Substance Abuse Treatment, 2002
- Impaired Cued and Contextual Memory in NPAS2-Deficient MiceScience, 2000
- Chronic morphine administration in cats: Effects on sleep and EEGPharmacology Biochemistry and Behavior, 1989
- Sleep Patterns in Human Methadone AddictionAddiction, 1978